Development of cell-selective targeting systems of NFκB decoy for inflammation therapy

Abstract

NFκB regulate several inflammatory related molecules and evoke immune and inflammatory response by several stimuli, therefore inhibition of NFκB activation would be a novel therapeutic strategy. To date, there are many conventional drugs including nonsteroldal or steroldal anti-inflammatory drugs or immune suppressors etc. were known to inhibit NFκB activation, however, several side effects were also reported. Recently, double stranded oligonucleotide including NFκB binding sequence, called NFκB decoy, was developed to prevent NFκB activation, which is powerful tool in a new class of anti-gene strategy for molecular therapy with low side effect. However, NFκB decoy is easily degraded by nuclease and rapidly excreted to urine, therefore it is necessary to develop carrier for NFκB decoy therapy. Here, we shall review delivery system for NFκB decoy and introduce our cell-selective delivery system for NFκB decoy using sugar decorated cationic liposomes. © 2008 The Pharmaceutical Society of Japan.